---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281498"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:54:10.819903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences Q3 net loss $25.2M; cash runway into H1 2028 after $135M placement

## Summary
- Q3 2025 net loss of $25.2M vs $16.3M loss in Q3 2024; R&D expenses $22.0M, G&A $5.4M.
- Cash, equivalents, and investments $198.9M at Sep 30; pro-forma ~$325.6M after $135M private placement closed in October.
- Phase 1 trial of JADE101 (anti-APRIL for IgAN) enrolled; interim biomarker data expected H1 2026.
- Unveiled JADE201 (anti-BAFF-R); first-in-human trial in rheumatoid arthritis planned for H1 2026.
- Private placement of $135M extended cash runway into first half of 2028.

## SEC filing metadata
- accession: 0001193125-25-281498
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/0001193125-25-281498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/d26766d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281498
- JSON: https://secwatch.observer/filing/0001193125-25-281498.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.